The FDA has approved the first eye-growth-suppressing eye drops from foundation medicine’s new growth-promoting line, EGF, which are designed to help treat people who have trouble controlling their eyelids.
The FDA approved EGF in August for people who are not able to control their eyelid, a condition called hyperpigmentation, and for people with hyperpapillosis, a complication of the cornea that occurs when too much collagen is trapped inside the corneal surface.
The EGFs come in two flavors: the first, a gel, is supposed to be taken twice a day, the second, a cream, lasts three to six hours, according to the FDA.
The two flavors of EGF are currently available at Walgreens, Target, Target.com, CVS, Walgens, Home Depot, Nordstrom, Target Pharmacy, and CVS Pharmacy.
The new products, which cost $16 to $20 a bottle, are a bit pricey for a line that doesn’t have an expiration date yet.
But for the first time, foundation medicine is able to say they can help treat a condition that was previously a rare condition, according the Wall Street Journal.
A report from the Journal said that since the new products were approved, more than half of the patients it surveyed had been treated with EGF.
“In some cases, it has improved the quality of life, and in other cases it has decreased the risk of recurrence,” foundation medicine spokesperson Melissa Smith said in a statement to the Journal.
“These are very encouraging data for the FDA.”
The FDA is also investigating whether the new EGF products have any side effects.
For more on eye-care, click here.
Follow CNN Health on Facebook and Twitter See more CNN Health: